Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy
Authors
Keywords
-
Journal
Breast Cancer
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-01
DOI
10.1007/s12282-023-01514-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Projected estimates of cancer in Canada in 2022
- (2022) Darren R. Brenner et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
- (2022) Sandra M. Swain et al. Cancers
- Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States
- (2021) Jesse Sussell et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
- (2021) Christian Jackisch et al. CANCER TREATMENT REVIEWS
- PCN2 Recurrences Avoided and Life Years Saved Attributable to Trastuzumab Use in HER2+ Early and Metastatic Breast Cancer in the United States
- (2021) M. Danese et al. VALUE IN HEALTH
- European cancer mortality predictions for the year 2019 with focus on breast cancer
- (2019) M Malvezzi et al. ANNALS OF ONCOLOGY
- The future burden of cancer in Canada: Long-term cancer incidence projections 2013–2042
- (2019) Abbey E. Poirier et al. Cancer Epidemiology
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
- (2018) Sara A Hurvitz et al. LANCET ONCOLOGY
- Using administrative data to identify and stage breast cancer cases: Implications for assessing quality of care
- (2018) Elaine Yuen et al. TUMORI
- Differences in Stage and Treatment of Breast Cancer across Italy Point to Inequalities in access to and Availability of Proper Care
- (2018) Pamela Minicozzi et al. TUMORI
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global treatment costs of breast cancer by stage: A systematic review
- (2018) Li Sun et al. PLoS One
- Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study
- (2017) Aviane Auguste et al. PLoS One
- Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab
- (2016) Ines Vaz-Luis et al. BREAST CANCER RESEARCH AND TREATMENT
- ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study
- (2016) Stacey DaCosta Byfield et al. Journal of Oncology Practice
- Second Malignancies After Adjuvant Radiation Therapy for Early Stage Breast Cancer: Is There Increased Risk With Addition of Regional Radiation to Local Radiation?
- (2015) Sarah Nicole Hamilton et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
- (2015) Mark D. Danese et al. VALUE IN HEALTH
- Health system costs for stage-specific breast cancer: a population-based approach
- (2014) N. Mittmann et al. Current Oncology
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
- (2014) E. C. Inwald et al. Biomed Research International
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer
- (2012) Michelle M. Kim et al. CANCER
- Breast cancer survival in the US and Europe: A CONCORD high-resolution study
- (2012) Claudia Allemani et al. INTERNATIONAL JOURNAL OF CANCER
- Factors associated with the prescription of antidepressive medication to breast cancer patients
- (2011) Nis P. Suppli et al. ACTA ONCOLOGICA
- Cost-effectiveness of early detection of breast cancer in Catalonia (Spain)
- (2011) Misericordia Carles et al. BMC CANCER
- Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation
- (2011) J. E. Panoff et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses
- (2011) Voralak Vichapat et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival
- (2010) Wendy A. Woodward et al. BREAST CANCER RESEARCH AND TREATMENT
- Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer
- (2010) Antonino Musolino et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now